|
1 Fung KF, Oliver T. Optimal chemotherapy treatment for women recurrent ovarian cancer. Curr Oncol, 2007, 14(5)：195–208.
|
|
2 Hales BF. Thalidomide on the comeback trail. Nat Med, 1999, 5(5)：489–490.
|
|
3 Gridelli C, Maione P, Rossi A, et al. The role of bevacizumab in the treatment of non–small cell lung cancer current indications and future development. Oncologist, 2007, 12：1183–1193.
|
|
4 EmLet DR, Brown KA，Kociban DL，et al.Response to trastuzum，erlotinib，and bevacizumab，alone and incombination，is correlated with the level of an epidermal grow the factor receptor–2 expression in human breast cancer cell lines. Mol Cancer Ther，2007，6：2664–2674.
|
|
5 Li W, Peng ZL，Cao ZY. Study of thalidomide on the growth of ovary cancer SKOV3 in vivo. Chin J Pract Genecol Obstet，2004，20(7)：429–430.[ 李文，彭芝兰，曹泽毅. 沙利度胺对人卵巢癌细胞株体外生长影响的研究．中国实用妇科与产科杂志，2004，20(7)：429–430.]
|
|
6 Li W, Peng ZL，Cao ZY. Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice. Chin J Obstet Genecol，2005，40930：186–189.[ 李文，彭芝兰，曹泽毅. 沙利度胺对人卵巢癌皮下移植瘤血管生成的影响．中华妇产科杂志，2005，40(3)：186–189.]
|
|
7 Abramson N，Stokes PK，Luke M，et al. Ovarian and papillary serous peritoneal carcinoma pilot study with thalidomide.Clin Oncol，2002，20：1147–1149.
|
|
8 Chan JK, Manuel MR, Ciaravino G, et al. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Gynecol Oncol，2006，103：919–923.
|
|
9 Zhang MM，Chan JK, Husain A，et al. Safety and efficacy of lenalidomide(Revlimid) in recurrent ovarian and primary peritoneal carcinoma. Gynecol Oncol，2007，105：194–198.
|
|
10 Fujimoto J，Sakaguchi H，Nirose R，et al. Biologic implication of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma.J Cancer，1998，83：2528–2533.
|
|
11 Veda M，Terai Y，Kumagai K，et al.Vascular endothelial growth factor C gene expression is closely related to invasion pheno type in gynecological tumor cells. J Gynecol Oncol, 2001，82：162–166.
|
|
12 Gordon N，Trebble TM，Ellis RD, et al.Thalidomide in the treatment of cancer cachexia a randomised placebo controlled trial. J Gut, 2005, 54：540–545.
|
|
13 Moreira AL，Sampaio EP，Zmnidzinas A，et al.Thalidomide exerts its inhibitory action necrosis factor alpha by enhancing mRNA degradation. J Exp Med，1993，177：1675–1680.
|
|
14 Dal Lago L，Richer MF, Cancela AI, et al. Phase 2 trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs，2003，21(3)：359–366.
|